The global hyperammonemia treatments market is expected to grow at a compound annual growth rate (CAGR) of 4.77% to reach a valuation of US$ 1,318.05 million in 2023 and US$ 2,100 million by 2033, according to a recent report by Future Market Insights.
The increased frequency of urea cycle diseases, as well as extensive research and development, are driving the growth of the Hyperammonemia treatment market. Increasing infrastructure development and government backing are expected to have an impact on market demand. The expanding public awareness of hyperammonemia and the increasing number of innovative diagnostic procedures are driving the expansion of the hyperammonemia treatment market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16383
Furthermore, research and development studies highlighting the genetic characteristics of Hyperammonemia would assist market participants in aligning their product development, hence contributing to market expansion. Nevertheless, long-term therapy difficulties, drug production, and diagnostic challenges are anticipated to limit the worldwide Hyperammonemia treatment market’s growth.
Key Takeaways:
- From 2023 to 2033, the global hyperammonemia therapy market is predicted to rise 1.6x.
- The United States is expected to lead the market in North America with a 48% market share.
- In terms of hyperammonemia treatment disbursement, South Asia is predicted to grow at a 4.2% CAGR.
- Glycerol phenylbutyrate is expected to account for 35.5% of the segment by the end of 2033.
- Hospital pharmacies will generate a segment share of around 48% by the end of the projection period.
- Product demand is predicted to increase as gene therapy for the treatment of hyperammonemia advances.
“Advancements in gene therapy and growing investments in Research & development for treatment of hyperammonemia will bolster product demand”, comments an FMI analyst
Competitive Landscape
The market is fragmented and moderately competitive. The strategies such as mergers and acquisitions adopted by major market players will boost the studied market growth. The major players in the market are: Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc, Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd, Abbott Laboratories, and Selecta Biosciences, Inc. Some recent developments in this industry are as follows:
- Acer Therapeutics and Relief Therapeutics Holding AG, a biopharmaceutical company, agreed into a collaboration and licence agreement in January 2021 to develop and commercialise acer-001, a sodium Phenylbutyrate drug combination for the treatment of urea cycle diseases.
- Versantis AG announced in July 2022 that the US Food and Drug Administration (FDA) had classified VS-01, an ammonia clearance booster, as a rare paediatric disease designation for the treatment of urea cycle disorders.
- According to Acer Therapeutics Inc. and its collaborative partner, RELIEF THERAPEUTICS, in October 2021. (UCDs). The FDA accepted the submission of the New Drug Application (NDA) for the medication ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders.
- In January 2021, Recordati Rare Diseases Inc. received the US Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia
More insights available:
North America is the largest hyperammonemia market due to the high prevalence of genetic disorders such as urea cycle disorders (UCD) in the region. The increasing awareness about these disorders and their treatment options, coupled with favorable reimbursement policies, is expected to drive the market growth in this region.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16383
Key Segments Profiled in the Hyperammonemia Treatment Market Industry Survey
By Treatment Type:
- Amino Acid Supplements
- Sodium Phenylbutyrate
- Glycerol Phenylbutyrate
- Sodium Benzoate
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
